Additionally, a study examining the indirect benefits of rotavirus vaccine in older children and young adults, a study in the USA estimated that approximately 8800 gastroenteritis hospitalizations were prevented among individuals 5–24 years of age in 2008 saving US$ 42 million in treatment costs [48]. The dramatic declines in rotavirus disease documented in middle and high income countries following vaccine

introduction, coupled with the high disease burden in low income countries like India suggest that large declines in the number of deaths, hospitalizations, and outpatient visits due to rotavirus gastroenteritis may be observed following vaccine introduction into the national immunization programs despite modest selleck chemical vaccine efficacy. [5] Thus, with the high rotavirus disease burden in India, rotavirus vaccines have substantial potential to prevent a large number of deaths, hospitalizations,

and outpatient visits due to rotavirus even with the modest efficacy. Data on rotavirus vaccine impact in developing countries are sparse due to Selleckchem ABT-263 limited use of rotavirus vaccines in these countries. This will change in the coming years with GAVI support and increased use of vaccines in developing countries. But it is important that Indian policy makers consider available data as early as possible. The benefits of rotavirus vaccination may extend beyond those which are expected among children <5 years of age. Indirect benefits of rotavirus vaccination have been observed in the early years of the rotavirus vaccination program in early adopter countries suggesting that rotavirus vaccine may offer some protection to those populations not directly covered by the immunization program. Little information is available about the incidence of rotavirus disease among older children and adults in most countries, including in India, but even if a small

unrecognized disease burden exists in these populations, the impact of rotavirus vaccines at the population level could be greater than anticipated. Further studies of disease burden among all ages and data from clinical trials or demonstration projects in India will help to determine the performance and project the L-NAME HCl impact of rotavirus vaccine introduction. India, like other developing countries, has documented tremendous diversity in circulating rotavirus strains [77], [78] and [79] (Fig. 3). Fortunately, substantial evidence suggests that rotavirus vaccines provide heterotypic protection against a wide range of genotypes. Secular trends in circulating strains continue to occur in countries that have introduced rotavirus vaccine. While it may be too soon to determine if vaccine pressure will result in the emergence of escape strains, both globally available vaccines have demonstrated effectiveness against multiple rotavirus strains.